Indo US Bio-Tech Ltd. (INDOUS): Indo US Bio-Tech Share Price Rises 8.47% Today on Market Attention
- September 4, 2026
- Posted by: Harsh Piplani
- Category: News
Indo US Bio-Tech Share Price moved sharply higher today, with the stock trading at Rs 88, up 8.47% from the previous close of Rs 81.13, and a market capitalisation of Rs 157.41 Cr. The latest Univest data confirms a clear share price gain, even though the numbers do not establish a company-specific catalyst. In that setting, Indo US Bio-Tech Stock News is drawing attention because the move sits alongside a modest valuation profile, stronger-than-benchmark return ratios and a small-cap market value that keeps every change in price visible. According to latest Univest data, the stock opened at Rs 76.7, touched a low of Rs 72.6 and reached Rs 88 during the day, which places Indo US Bio-Tech Share Price near the session high as of 04 September 2026 at 9:35:19 AM IST.
For investors tracking Indo US Bio-Tech Share Price Today, the key question is not just the rise itself but what the market is pricing in. The present move makes Indo US Bio-Tech Share Price relevant for stock analysis, fundamental analysis and broader Indian stock market screening, especially within the Agri space.
Indo US Bio-Tech Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 88 |
| Previous Close | Rs 81.13 |
| Today's Move | Rs 6.87 (+8.47%) |
| Open | Rs 76.7 |
| High | Rs 88 |
| Low | Rs 72.6 |
| Turnover | Rs 0.04 crore |
| Market Capitalisation | Rs 157.41 crore |
| Market Cap Category | Micro Cap |
Indo US Bio-Tech Ltd. (INDOUS) rose to Rs 88 from the previous close of Rs 81.13, a move of Rs 6.87 or 8.47%. The stock opened at Rs 76.7, reached a high of Rs 88, recorded a low of Rs 72.6.
Indo US Bio-Tech Share Price Today shows a Rs 6.87 increase, or 8.47%, from the previous close, with the stock last traded at Rs 88. The day opened at Rs 76.7, moved down to Rs 72.6, and later touched Rs 88, matching the day high. Turnover stood at Rs 0.04 Cr, which keeps the move compact in monetary terms while still making Indo US Bio-Tech Share Price one of the more closely watched names in today’s Stocks in News list. The price action indicates a strong intraday bounce and keeps Indo US Bio-Tech Stock Gaining Today on trader and investor screens.
Indo US Bio-Tech Ltd. (INDOUS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 157.41 crore |
| P/E Ratio | 14.2x |
| P/B Ratio | 1.7x |
| ROE | 23.03% |
| ROCE | 21.15% |
| EPS | Rs 5.71 |
| Book Value Per Share | Rs 47.66 |
| Dividend Yield | 0% |
Indo US Bio-Tech Ltd. (INDOUS) fundamental metrics show P/E 14.2x, P/B 1.7x, ROE 23.03%, ROCE 21.15%. These figures provide context only and are not a buy or sell signal.
Indo US Bio-Tech Ltd. has a market capitalisation of Rs 157.41 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 14.2x, P/B at 1.7x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.03% and ROCE of 21.15%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 5.71, book value per share of Rs 47.66, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 14.2x, median ROE of 9.13%, median ROCE of 11.57%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Agri |
| Industry | Agriculture |
| Benchmark Scope | same industry |
| Company P/E Ratio | 14.2x |
| Benchmark Median P/E | 14.2x |
| Benchmark Average P/E | 59.13x |
| Benchmark P/E Range | 1.29x to 533.25x |
| Company P/B Ratio | 1.7x |
| Benchmark Median P/B | 1.44x |
| Company ROE | 23.03% |
| Benchmark Median ROE | 9.13% |
| Company ROCE | 21.15% |
| Benchmark Median ROCE | 11.57% |
| Company Market Capitalisation | Rs 157.41 crore |
| Benchmark Median Market Cap | Rs 78.67 crore |
Indo US Bio-Tech Ltd. (INDOUS) is classified under sector: Agri and industry: Agriculture.
Indo US Bio-Tech Ltd. (INDOUS) has a P/E ratio of 14.2x, which is equal to the benchmark median of 14.2x, a difference of 0%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Indo US Bio-Tech Ltd. (INDOUS) has a ROE of 23.03%, which is above the benchmark median of 9.13%, a difference of +152.25%. Indo US Bio-Tech Ltd. (INDOUS) has a ROCE of 21.15%, which is above the benchmark median of 11.57%, a difference of +82.8%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Bombay Burmah Trading Corporation Ltd. | BBTC | 10,423.57 | 8.12 | 1.37 | 39.44 | 44.26 |
| Kaveri Seed Company Ltd. | KSCL | 3,807.78 | 15.37 | 1.88 | 20.67 | 21.77 |
| Venky'S (India) Ltd. | VENKEYS | 2,334.91 | 13.62 | 1.44 | 8.2 | 11.27 |
| AVT Natural Products Ltd. | AVTNPL | 1,327.92 | 16.63 | 2.36 | 12.16 | 14.26 |
| Freshara Agro Exports Ltd. | FRESHARA | 1,033.38 | 28.53 | 8.09 | 37.23 | 24.97 |
Indo US Bio-Tech Ltd. (INDOUS) has a P/E ratio of 14.2x compared with the displayed peer median of 15.37x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.03% compares with a peer median of 20.67% across the companies shown in the table. ROCE stood at 21.15% versus the displayed peer median of 21.77%, providing a capital-efficiency comparison. Indo US Bio-Tech Ltd. (INDOUS) has a market capitalisation of Rs 157.41 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Indo US Bio-Tech
- Indo US Bio-Tech Share Price rose 8.47% today, keeping it among the day’s notable shares gaining today.
- The stock traded at Rs 88, very near the day high of Rs 88, which makes the price action worth tracking.
- P/E at 14.2 and P/B at 1.7 give Indo US Bio-Tech Share Price a defined valuation base.
- ROE of 23.03% and ROCE of 21.15% place the business above key sector medians.
- The Agri sector comparison shows Indo US Bio-Tech Share Price as a smaller company with above-median returns.
About Indo US Bio-Tech
Indo US Bio-Tech Ltd. operates in the Agri sector and the Agriculture industry. The company is best viewed through the lens of crop-related business activity, where operating efficiency and earnings quality matter for market interest. Its latest market cap of Rs 157.41 Cr places it among smaller listed agri names, so the Indo US Bio-Tech Share Price can respond sharply to changes in sentiment and valuation perception.
For readers following Indo US Bio-Tech Company News, the main appeal lies in the company’s financial profile rather than in a broad market-cap story. EPS of Rs 5.71, book value of Rs 47.66 and ROE of 23.03% together help frame the business as one with measurable return strength. That is why Indo US Bio-Tech Stock News continues to attract attention across Univest screens, especially when price rises bring the stock into active discussion.
Frequently Asked Questions
Why is Indo US Bio-Tech Share Price rising today?
Ans. Indo US Bio-Tech Share Price is up 8.47% today, with the stock trading at Rs 88 versus Rs 81.13 earlier. The latest Univest data confirms the move, but it does not establish a company-specific catalyst.
What is Indo US Bio-Tech Share Price Today?
Ans. Indo US Bio-Tech Share Price Today is Rs 88. The stock added Rs 6.87 from the previous close and touched a day high of Rs 88, which keeps the move firmly in focus.
What is Indo US Bio-Tech market capitalisation now?
Ans. Indo US Bio-Tech currently has a market capitalisation of Rs 157.41 Cr. That size places it in the small-cap category and helps explain why even a single-day move can draw attention.
How does Indo US Bio-Tech compare on valuation?
Ans. Indo US Bio-Tech trades at a P/E of 14.2 and a P/B of 1.7. The P/E matches the industry median, while the P/B sits above the median but below several higher-priced agri peers.
What do Indo US Bio-Tech earnings ratios show?
Ans. Indo US Bio-Tech reports ROE of 23.03% and ROCE of 21.15%. Both are above the sector medians, indicating stronger return generation than the typical company in the same industry set.
What is Indo US Bio-Tech EPS and book value?
Ans. EPS stands at Rs 5.71 and book value is Rs 47.66. EPS reflects earnings attributable to each share, while book value shows the accounting net worth behind each share.
Does Indo US Bio-Tech pay a dividend?
Ans. The dividend yield is 0, so the stock’s current appeal is tied more to valuation and return ratios than to income. Investors watching Indo US Bio-Tech Share Price are therefore focused on fundamentals.
How does Indo US Bio-Tech look versus its Agri peers?
Ans. Indo US Bio-Tech sits near the middle on valuation and above many peers on return ratios. Its market cap is smaller than several listed agriculture names, but its ROE and ROCE remain competitive.
Track Indo US Bio-Tech Share Price on Univest
Use Indo US Bio-Tech Ltd. (INDOUS) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Investors can track Indo US Bio-Tech Share Price on Univest for live price movement, market capitalisation, valuation ratios, financial analysis, sector context, peer comparison and latest stock updates. Univest also helps users follow key stock performance metrics for faster screening and better market monitoring.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
